Dawnzera is designed to inhibit plasma prekallikrein, a significant activator of the inflammatory mediators that cause acute HAE attacks. This 80mg dose of the medicine is self-administered through a ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.

BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both ...

Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Ionis on Thursday said the FDA green light covers Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in patients 12 years of age and older and makes the drug is the first and only ...